Healthcare -
Biotechnology - NASDAQ - US
$ 0.1698
-5.67 %
$ 82.8 M
Market Cap
None
P/E
1. INTRINSIC VALUE
Balance Sheet
Reviva Pharmaceuticals Holdings, Inc.
| Current Assets | 23.7 M |
| Cash & Short-Term Investments | 23.4 M |
| Receivables | 0 |
| Other Current Assets | 333 K |
| Non-Current Assets | 0 |
| Long-Term Investments | 0 |
| PP&E | 0 |
| Other Non-Current Assets | 0 |
| Current Liabilities | 17.2 M |
| Accounts Payable | 3.85 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 13.3 M |
| Non-Current Liabilities | 807 K |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 807 K |
EFFICIENCY
Earnings Waterfall
Reviva Pharmaceuticals Holdings, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 39.5 |
| Operating Income | (39.5) |
| Other Expenses | (39.5) |
| Net Income | -39.3 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Reviva Pharmaceuticals Holdings, Inc.
| Net Income | -39.3 M |
| Depreciation & Amortization | 0 |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 3.41 M |
| Change in Working Capital | 7.28 M |
| Others | 7.19 M |
| Free Cash Flow | -28.3 M |
Wall Street Analysts Price Targets
Reviva Pharmaceuticals Holdings, Inc.
RVPHW has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
RVPHW does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Reviva Pharmaceuticals Holdings, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
2 years ago
Nov 18, 2022
|
Bought
14.1 K USD
|
Patel Purav
Director
|
+ 3000
|
4.69 USD |
|
2 years ago
Sep 08, 2022
|
Bought
2.09 M USD
|
VEDANTA PARTNERS, LLC
10 percent owner
|
+ 869565
|
2.4 USD |
|
2 years ago
Sep 08, 2022
|
Bought
87 USD
|
VEDANTA PARTNERS, LLC
10 percent owner
|
+ 869565
|
0.0001 USD |
|
2 years ago
Sep 08, 2022
|
Bought
51.4 USD
|
VEDANTA PARTNERS, LLC
10 percent owner
|
+ 513834
|
0.0001 USD |
|
2 years ago
Sep 08, 2022
|
Bought
1.23 M USD
|
VEDANTA PARTNERS, LLC
10 percent owner
|
+ 513834
|
2.4 USD |
|
3 years ago
Jun 01, 2021
|
Bought
3.84 M USD
|
VEDANTA PARTNERS, LLC
10 percent owner
|
+ 931000
|
4.125 USD |
|
3 years ago
Jun 01, 2021
|
Bought
3.49 M USD
|
VEDANTA PARTNERS, LLC
10 percent owner
|
+ 931000
|
3.75 USD |
|
3 years ago
Jun 01, 2021
|
Bought
1.65 M USD
|
VEDANTA PARTNERS, LLC
10 percent owner
|
+ 399000
|
4.125 USD |
|
3 years ago
Jun 01, 2021
|
Bought
1.5 M USD
|
VEDANTA PARTNERS, LLC
10 percent owner
|
+ 399000
|
3.75 USD |
|
4 years ago
Dec 08, 2020
|
Sell 3.99 M
USD
|
GLAZER CAPITAL, LLC
10 percent owner
|
- 367000
|
10.88 USD |
|
4 years ago
Dec 07, 2020
|
Sell 576 K
USD
|
Hudson Bay Capital Management LP
10 percent owner
|
- 50000
|
11.51 USD |
|
4 years ago
Dec 02, 2020
|
Sell 2.87 K
USD
|
GLAZER CAPITAL, LLC
10 percent owner
|
- 261
|
11 USD |
|
4 years ago
Nov 27, 2020
|
Sell 65.1 K
USD
|
GLAZER CAPITAL, LLC
10 percent owner
|
- 5969
|
10.9 USD |
|
4 years ago
Dec 01, 2020
|
Sell 59 K
USD
|
GLAZER CAPITAL, LLC
10 percent owner
|
- 5362
|
11 USD |
|
4 years ago
Nov 23, 2020
|
Sell 257 K
USD
|
GLAZER CAPITAL, LLC
10 percent owner
|
- 23611
|
10.9 USD |
|
4 years ago
Nov 24, 2020
|
Sell 77.4 K
USD
|
GLAZER CAPITAL, LLC
10 percent owner
|
- 7103
|
10.9 USD |
|
4 years ago
Nov 16, 2020
|
Sell 3.32 K
USD
|
GLAZER CAPITAL, LLC
10 percent owner
|
- 305
|
10.9 USD |
|
4 years ago
Nov 17, 2020
|
Sell 1.38 K
USD
|
GLAZER CAPITAL, LLC
10 percent owner
|
- 127
|
10.9 USD |
|
4 years ago
Nov 18, 2020
|
Sell 9.77 K
USD
|
GLAZER CAPITAL, LLC
10 percent owner
|
- 896
|
10.9 USD |
|
4 years ago
Nov 11, 2020
|
Sell 54.5
USD
|
GLAZER CAPITAL, LLC
10 percent owner
|
- 5
|
10.9 USD |
|
4 years ago
Nov 06, 2020
|
Sell 10.9
USD
|
GLAZER CAPITAL, LLC
10 percent owner
|
- 1
|
10.9 USD |
|
4 years ago
Nov 02, 2020
|
Sell 11.5
USD
|
GLAZER CAPITAL, LLC
10 percent owner
|
- 1
|
11.5 USD |
|
4 years ago
Nov 03, 2020
|
Sell 625 K
USD
|
GLAZER CAPITAL, LLC
10 percent owner
|
- 57616
|
10.85 USD |
|
4 years ago
Mar 20, 2020
|
Bought
104 K USD
|
Hudson Bay Capital Management LP
10 percent owner
|
+ 10000
|
10.37 USD |
|
4 years ago
Nov 02, 2020
|
Sell 544 K
USD
|
Hudson Bay Capital Management LP
10 percent owner
|
- 50000
|
10.87 USD |
|
4 years ago
Sep 29, 2020
|
Sell 23
USD
|
GLAZER CAPITAL, LLC
10 percent owner
|
- 2
|
11.5 USD |
|
4 years ago
Sep 17, 2020
|
Sell 10.8 K
USD
|
GLAZER CAPITAL, LLC
10 percent owner
|
- 1000
|
10.8 USD |
|
4 years ago
Sep 14, 2020
|
Sell 10.8
USD
|
GLAZER CAPITAL, LLC
10 percent owner
|
- 1
|
10.8 USD |
|
4 years ago
May 08, 2020
|
Sell 542 K
USD
|
MIZUHO SECURITIES USA LLC
10 percent owner
|
- 51000
|
10.62 USD |
|
6 years ago
Aug 30, 2018
|
Bought
330 K USD
|
Tenzing LLC
10 percent owner
|
+ 33000
|
10 USD |
|
6 years ago
Aug 30, 2018
|
Bought
330 K USD
|
Nayar Rahul
Chief Executive Officer
|
+ 33000
|
10 USD |
|
6 years ago
Aug 30, 2018
|
Bought
330 K USD
|
SAXENA PARAG
Chairman of the Board
|
+ 33000
|
10 USD |
|
6 years ago
Aug 23, 2018
|
Bought
3.1 M USD
|
Nayar Rahul
Chief Executive Officer
|
+ 310000
|
10 USD |
|
6 years ago
Aug 23, 2018
|
Bought
3.1 M USD
|
SAXENA PARAG
Chairman of the Board
|
+ 310000
|
10 USD |
|
6 years ago
Aug 23, 2018
|
Bought
3.1 M USD
|
Tenzing LLC
10 percent owner
|
+ 310000
|
10 USD |
7. News
8. Profile
Summary
Reviva Pharmaceuticals Holdings, Inc. RVPHW
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 82.8 M
Dividend Yield
0.00%
Description
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company was founded in 2018 and is based in Cupertino, California.
Contact
19925 Stevens Creek Boulevard, Cupertino, 95014
https://www.revivapharma.com
IPO
Date
None
Employees
15
Officers
Dr. Laxminarayan Bhat Ph.D.
Founder, Chief Executive Officer, President & Director
Mr. Narayan Prabhu
Chief Financial Officer